What is the Fiscal Year for Lyra Therapeutics?
Date: November 14, 2026
Lyra Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Watertown, Massachusetts, United States
Industry
Healthcare, Biotechnology Research Services
Stock Symbol
LYRA
Website
https://lyratherapeutics.comDescription
Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. Building on expertise in materials science, drug development and formulation, Lyra has developed proprietary technology that is designed to deliver medicines directly precisely and consistently to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, in-office procedure and intended to deliver up to six months of continuous mometasone furoate drug therapy to the sinonasal passages for the treatment of CRS.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Lyra Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.